【Case Study】Route, Solid-State, and Impurity Optimization (Small-Molecule API)

Facebook
LinkedIn
Route, Solid-State, and Impurity Optimization (Small-Molecule API)

Program Type: Small-molecule API
CMC Focus: Route optimization, solid-state control, impurity management

Overview

In a separate small-molecule program, Medicilon re-engineered the API synthetic route and solid form strategy to significantly improve manufacturability, safety, and analytical control. The work integrated process chemistry, solid-state science, and analytical development under a unified CMC framework.

Key Outcomes

  • Route simplification and yield improvement:
    Reduced steps to a key intermediate from 7 to 4, increasing yield from <5% to >20%, while eliminating a malodorous sulfur reagent and avoiding reliance on SFC chiral separation.
  • Robust solid-form selection:
    Identified an optimal salt form through comparative XRPD and crystallization screening, followed by tailored crystallization methods to generate high-quality single crystals for structure confirmation and IP support.
  • Enhanced impurity and solvent control:
    Reduced residual solvents using a toolbox of 20+ crystallization and drying strategies, and upgraded analytical methods to clearly resolve and control previously overlapping impurities.

Route/step and yield optimization:

 

  1. Improve efficiency

 The liner sequence steps were reduced from 12 to 7, total yield was increased from <1% to >10%l, no silica gel column purtications were needed.

2. Reduce steps

Medicilon reduced the route to the key intermediate from seven to four steps and increased yield from less than 5 to over 20 by redesigning the CMC API process.

Solid State R&D Platform:

1.) Salt and Crystalline” (XRPD of HCl vs malic acid salt).

2.) Crystalline Form” (conventional vs novel crystallization methods to obtain single crystals).

Solvent residue and impurity control:

1.) Solvent Residue Removal: 20+ classic and self‑developed methods to reduce solvent residue

2.) API analytical methods

  • Original analytical Method Spectrum:

Related impurities could not be completely separated

  • Analytical Method Spectrum after optimization

Related impurities could be effectively separated

Search Medicilon

Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche

Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche

AACR 2026

【Case Study】Route, Solid-State, and Impurity Optimization (Small-Molecule API)

Contact Medicilon

Name(Required)
Address(Required)